These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 16096858

  • 1. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin.
    Rotschild M, Elias N, Berkowitz D, Pollak S, Shinawi M, Beck R, Bentur L.
    Clin Exp Med; 2005 Jul; 5(2):80-5. PubMed ID: 16096858
    [Abstract] [Full Text] [Related]

  • 2. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis.
    Dorlöchter L, Carlsson M, Olafsdottir EJ, Røksund OD, Rosendahl K, Fluge G.
    J Cyst Fibros; 2004 Aug; 3(3):179-83. PubMed ID: 15463905
    [Abstract] [Full Text] [Related]

  • 3. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis.
    Carlsson M, Eriksson L, Pressler T, Kornfält R, Mared L, Meyer P, Wiik A, Wieslander J, Segelmark M.
    J Cyst Fibros; 2007 May; 6(3):228-33. PubMed ID: 17166780
    [Abstract] [Full Text] [Related]

  • 4. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.
    Schultz H, Schinke S, Mosler K, Herlyn K, Schuster A, Gross WL.
    Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661
    [Abstract] [Full Text] [Related]

  • 5. Extensive endoscopic image-guided sinus surgery decreases BPI-ANCA in patients with cystic fibrosis.
    Aanaes K, Rasmussen N, Pressler T, Segelmark M, Johansen HK, Lindberg U, Høiby N, Carlsson M, Wieslander J, Buchwald C.
    Scand J Immunol; 2012 Dec; 76(6):573-9. PubMed ID: 22946777
    [Abstract] [Full Text] [Related]

  • 6. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.
    Aichele D, Schnare M, Saake M, Röllinghoff M, Gessner A.
    Infect Immun; 2006 Aug; 74(8):4708-14. PubMed ID: 16861658
    [Abstract] [Full Text] [Related]

  • 7. Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies.
    Carlsson M, Eriksson L, Erwander I, Wieslander J, Segelmark M.
    Clin Exp Rheumatol; 2003 Aug; 21(6 Suppl 32):S95-100. PubMed ID: 14740434
    [Abstract] [Full Text] [Related]

  • 8. Pseudomonas aeruginosa in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease.
    Carlsson M, Shukla S, Petersson AC, Segelmark M, Hellmark T.
    J Cyst Fibros; 2011 Jul; 10(4):265-71. PubMed ID: 21463973
    [Abstract] [Full Text] [Related]

  • 9. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G, Schmitt-Grohe S, Döring G, Staab D, Pfründer D, Beck G, Schubert R, Zielen S.
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.
    Mahadeva R, Dunn AC, Westerbeek RC, Sharples L, Whitehouse DB, Carroll NR, Ross-Russell RI, Webb AK, Bilton D, Lomas DA, Lockwood CM.
    Clin Exp Immunol; 1999 Sep; 117(3):561-7. PubMed ID: 10469063
    [Abstract] [Full Text] [Related]

  • 13. The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies.
    Schultz H, Weiss J, Carroll SF, Gross WL.
    J Leukoc Biol; 2001 Apr; 69(4):505-12. PubMed ID: 11310835
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
    Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL.
    Pediatr Pulmonol; 2007 Jun; 42(6):533-41. PubMed ID: 17469154
    [Abstract] [Full Text] [Related]

  • 16. From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI).
    Schultz H.
    Autoimmun Rev; 2007 Mar; 6(4):223-7. PubMed ID: 17317612
    [Abstract] [Full Text] [Related]

  • 17. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.
    Khanna D, Aggarwal A, Bhakuni DS, Dayal R, Misra R.
    J Rheumatol; 2003 Jun; 30(6):1248-52. PubMed ID: 12784398
    [Abstract] [Full Text] [Related]

  • 18. Anti-neutrophil cytoplasmic antibodies (ANCA) in serum and bronchoalveolar lavage fluids of cystic fibrosis patients and patients with idiopathic bronchiectasis.
    Cobanoğlu N, Ozcelik U, Cetin I, Yalçin E, Doğru D, Kiper N, Bakkaloğlu A.
    Turk J Pediatr; 2010 Jun; 52(4):343-7. PubMed ID: 21043377
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
    Wilms EB, Touw DJ, Heijerman HG.
    Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
    [Abstract] [Full Text] [Related]

  • 20. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.
    Schultz H, Csernok E, Schuster A, Schmitz TS, Ernst M, Gross WL.
    Pediatr Allergy Immunol; 2000 May; 11(2):64-70. PubMed ID: 10893006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.